首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1643895

全球注射給藥市場 - 2025-2033

Global Injectable Drug Delivery Market - 2025-2033

出版日期: 2025年01月27日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球注射給藥市場達7.443億美元，預計到2033年將達到12.584億美元，2025-2033年預測期間複合年成長率為5.8%。

注射給藥系統是透過注射給藥的方法，可採用控釋和緩釋的水凝膠製劑。該系統旨在透過使用許多原位凝膠系統來提供延長釋放。這種方法大大增強了藥物的有效輸送，因為藥物在體內的引入將被延長，這將改善治療效果並增強患者對治療的依從性。

市場動態：

驅動程式和限制

慢性病盛行率上升

癌症和糖尿病等慢性疾病發生率的激增需要滲透性技術來輸送藥物。侵入性技術的廣泛接受程度將極大地決定全球注射給藥市場的成長速度。訓練有素的醫療專家的存在增強了他們的優勢。

例如，2024 年1 月，北卡羅來納州教堂山這所不起眼的大學的科學家們制定了一種獨特的藥物輸送方法，稱為時空按需貼片(SOP)，該方法允許透過單一微針安排和觸發藥物釋放。其薄而柔軟的貼片平台的設計很像創可貼，以提高穿戴式性，從而提高用戶的舒適度和便利性，因為這是涉及慢性病患者的關鍵因素。

男性和女性魯爾成分此外，美國自體免疫的盛行率是根據出版物和來自斯堪的納維亞國家等規模較小、流行病學資源豐富的國家的原始資料補充收集來估計的。據估計，所有自體免疫疾病的盛行率合計約為 3% 的美國人口受到影響——有證據表明，有數百萬人（推測約有 1000 萬人）受到影響。

複雜製造

全球注射給藥市場面臨多項挑戰，包括複雜的製造、患者依從性問題、來自口服、經皮和吸入系統等替代方法的競爭，以及低收入和中等收入國家冷鏈儲存和分銷基礎設施有限。這些因素可能會限制市場的成長潛力，因為它們限制了可近性並阻礙了注射治療的廣泛採用。注射製劑製造的複雜性、對針頭和相關疼痛的恐懼，以及低收入和中等收入國家冷鏈儲存和分銷基礎設施有限，進一步限制了市場的成長潛力。

有關此報告的更多詳細資訊 - 索取樣本

Baxter International, Inc
Gerresheimer AG
Pfizer Inc
Schott AG
Terumo Corporation
SHL Medical
Owen Mumford
Ypsomed
Union Medico
Similar data will be provided for each market player.
APIJect系統
- 管道產品說明
- 產品關鍵績效指標 (KPI)
- 主要活動
- 市場進入時間表
- 產品滲透率
- 銷售估算與預測
奧特根公司
鹵酶療法
卡莫特療法
將為每個市場參與者提供類似的資料。

第 12 章：附錄

簡介目錄

Product Code: MD799

The global injectable drug delivery market reached US$ 744.3 million in 2024 and is expected to reach US$ 1258.4 million by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033.

Injectable drug delivery systems are method which are administred through injection, which can be adapted in terms of hydrogel formulations that controlled and sustained release. The systems are intended to provide prolonged release by using many in situ gel systems. This approach tremendously augments the efficacious delivery of drugs as the introduction of medications in the body will be prolonged, which will improve the results of therapeutics and enhance patients' adherence to treatment.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Chronic Diseases

The upsurging of chronic diseases incidence such as cancer and diabetes have warranted penetrating technologies to deliver drugs. Where the mass acceptance of invasive techniques will greatly determine the rate of growth of the global injectable drug delivery market. Availability of trained medical experts has promoted their advantages.

For instance, in January 2024, Scientists from this humble University at Chapel Hill in North Carolina formulated a unique method of drug delivery known as the Spatiotemporal On-Demand Patch (SOP) that allows drug release from individual microneedles to be scheduled and triggered via a smartphone or computer command system. Its thin and soft patch platform is designed much like a Band-Aid in order to promote wearability, hence, comfort and convenience for users because this is a key factor involving chronically ill patients.

Male and Female Luer ComponentsMoreover, the prevalence of autoimmunities in the US has been estimated on the basis of publications and a supplementary collection of primary data from smaller, well-endowed epidemiological resources states like Scandinavian countries. Estimated combined prevalence of all autoimmune conditions is such that about 3% of the US population is affected-evidence to suggest that some millions, presumes about 10 million people are afflicted.

Complex Manufacturing

The global injectable drug delivery market faces several challenges, including complex manufacturing, patient compliance concerns, competition from alternative methods like oral, transdermal, and inhalation systems, and limited infrastructure for cold chain storage and distribution in low- and middle-income countries. These factors can limit the market's growth potential, as they restrict accessibility and hinder the widespread adoption of injectable treatments. The complexity of manufacturing injectable formulations, the fear of needles and associated pain, and the limited infrastructure for cold chain storage and distribution in low- and middle-income countries further limit the market's potential for growth.

For more details on this report - Request for Sample

Segment Analysis

The global injectable drug delivery market is segmented based on device type, application, usage pattern distribution channel and region.

Device Type:

Autoinjectors from the device segment is expected to dominate the Injectable Drug Delivery market share

The autoinjectors segment holds a major portion of the injectable drug delivery market share and is expected to continue to hold a significant portion of the injectable drug delivery market share during the forecast period.

Autoinjectors segment is expected to grow during the forecast period owing to the factors like siginificant product launches, advancements, moreover, autoinjectors are intuitive and user-friendly designed, requiring only a single button press to administer medication, minimizing errors and ensuring accurate dosing. However, they are not designed for multiple uses, raising sustainability concerns. Despite this, their user-friendly use continues to drive their popularity, with Nemera's PenDURA and PenVARIO platforms facilitating multi-dose pen injector ranges.

For instance, in June 2024, Instron announced the next-generation Autoinjector Testing System for complete functionality testing of pen and autoinjectors to ISO 11608. Developed in close cooperation with pharmaceutical companies and CDMOs, this system allows for measurement of a mixture of essential performances: cap removal, dose accuracy, activation force, injection time, needle depth, and needle guard lockout.

Moreover, in January 2024, Taisho Pharmaceutical Co., Ltd. has announced the launch of Nanozora 30mg Autoinjector for S.C. Injection, a TNFa inhibitor. This single-use autoinjector dosage form, prefilled with the same drug as the syringe dosage form, was launched in December 2022. The device is designed for ease of use, allowing users to inject the drug by pressing against the skin. The needle covering is locked after injection to prevent needle piercing accidents.

Application:-

Oncology segment is the fastest-growing segment in Injectable Drug Delivery market share

The oncology segment is the fastest-growing segment in the injectable drug delivery market share and is expected to hold the market share over the forecast period.

The oncology segment is driving growth in the global injectable drug delivery market, driven by the increasing prevalence of cancer worldwide. With approximately 20 million new cancer cases reported in 2023, the need for effective treatment options is urgent. Injectable drug delivery systems are advantageous in oncology due to their ability to administer complex biologics and immunotherapies for targeted cancer treatments.

Moreover, key market players are developing advanced injectable devices and formulations, including self-injectable devices and smart injectors, to enhance patient compliance and minimize dosing errors and also launching novel products help the segmet to grow during the forecast period.

For instance, Amneal Pharmaceuticals, Inc. announced the launch of PEMRYDI RTU, the first and the only ready-to-use presetation of pemetrexed for injection. Unlike other presentations, this product does not require the cool condition of reconstitution and dilution.

Geographical Analysis

North America is expected to hold a significant position in the Injectable Drug Delivery market share

North America holds a substantial position in the injectable drug delivery market and is expected to hold most of the market share due to increasing burden of chronic illnesses among adults, particularly diabetes, cancer, and autoimmune disorders. Besides, advanced healthcare infrastructure, hefty investment in research and development, and the organization of leading pharmaceutical firms all make the region a great potential market contributor. Moreover, when favorably wrapped with increasing self-injection, such as with insulin pens and further biologics, the reimbursement policies are sufficient to drive up this growing market.

For instance, in October 2023, Enable Injections has received FDA approval for the EMPAVELI Injector for subcutaneous delivery of EMPAVELI (pegcetacoplan), a medication for adults with paroxysmal nocturnal hemoglobinuria. The compact, wearable injector streamlines self-administration and minimizes disruption to patients' daily lives, making it a valuable tool for the treatment of PNH.

Europe is growing at the fastest pace in the Injectable Drug Delivery market

Europe holds the fastest pace in the injectable drug delivery market and is expected to hold most of the market share due to Europe has a good regulatory framework in most major markets, thus favoring uptake of these advanced injectable solutions. The focus on patient-driven drug delivery - such as prefilled syringes - is increasing across Europe, while treatment modalities are directed at home to avoid and limit hospital visits. The investment opportunity in this market further solidifies Europe's foothold in the expansion of the market. The current condition of an aging population with an upsurge incidence of chronic diseases across the region is what drives demand for injectable therapy.

For instance, in November 2024, Swiss medical technology company Ypsomed's has signed a new contract with Danish drugmaker Novo Nordisk, which includes the supply of injection pens for CagriSema, the company's next-generation experimental obesity drug. This deal provides insight into Novo's long-term planning for commercial production for its drug candidates, which are still being tested and hoped to be more powerful successors to its popular Wegovy injection.

Competitive Landscape

The major global players in the injectable drug delivery market include Becton Dickinson & Company, Baxter International, Inc, Gerresheimer AG, Pfizer Inc, Schott AG, Terumo Corporation, SHL Medical, Owen Mumford, Ypsomed, Union Medico and among others.

Key Developments

In January 2024, Credence MedSystems, a leading pharmaceutical drug delivery system innovator, has completed Factory Acceptance Testing (FAT) for the production of its Companion injection device platform on its new Clinical Assembly Line.
In June 2023, Stevanato Group, S.p.A., has introduced Vertiva, an On-Body Delivery System (OBDS) designed for switching between basal and bolus injections and suitable for various subcutaneous therapies. The unique design includes a single-use pod with a pre-filled 3mL ISO cartridge and a multi-use controller, offering sustainability and affordability benefits. The device can adapt to different delivery profiles and administer small-molecule drugs and biologics.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global injectable drug delivery market report delivers a detailed analysis with 70 key tables, more than 66 visually impactful figures, and 186 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Device Type
3.2. Snippet by Application
3.3. Snippet by Usage Patterns
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the Prevalence of Chronic Diseases
- 4.1.2. Restraints
  - 4.1.2.1. Complex Manufacturing
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Device Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 6.1.2. Market Attractiveness Index, By Device Type
6.2. Autoinjectors*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Conventional injection devices
6.4. Pen Injectors
6.5. Wearable injectors
6.6. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Oncology*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Autoimmune Diseases
- 7.2.4. Hormonal Disorders
- 7.2.5. Orphan Disease
- 7.2.6. Others

8. By Usage Pattern

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
- 8.1.2. Market Attractiveness Index, By Usage Pattern
8.2. Curative Care*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Immunization
8.4. Other Usage Pattern

9. By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

12.1. Becton Dickinson & Company*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio
  - 12.1.2.1. Product Description
  - 12.1.2.2. Product Key Performance Indicators (KPIs)
  - 12.1.2.3. Historic and Forecasted Product Sales
  - 12.1.2.4. Product Sales Volume
- 12.1.3. Financial Overview
  - 12.1.3.1. Company Revenue's
  - 12.1.3.2. Geographical Revenue Shares
  - 12.1.3.3. Revenue Forecasts
- 12.1.4. Key Developments
  - 12.1.4.1. Mergers & Acquisitions
  - 12.1.4.2. Key Product Development Activities
  - 12.1.4.3. Regulatory Approvals etc.
- 12.1.5. SWOT Analysis
12.2. Baxter International, Inc
12.3. Gerresheimer AG
12.4. Pfizer Inc
12.5. Schott AG
12.6. Terumo Corporation
12.7. SHL Medical
12.8. Owen Mumford
12.9. Ypsomed
12.10. Union Medico
Similar data will be provided for each market player.

Emerging Market Players

12.11. ApiJect Systems*
- 12.11.1. Pipeline Products Description
- 12.11.2. Product Key Performance Indicators (KPIs)
- 12.11.3. Key Activities
- 12.11.4. Market Entry Timelines
- 12.11.5. Product Penetration Rate
- 12.11.6. Sales Estimation and Projections
12.12. Alteogen Inc
12.13. Halozyme Therapeutics
12.14. Carmot Therapeutics
Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE